MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1245/s10434-024-15199-8

Медицинская библиотека · Annals of surgical oncology · 2024

Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015).

Yamada Daisaku, Kobayashi Shogo, Takahashi Hidenori, Iwagami Yoshifumi, Akita Hirofumi, Asukai Kei, Shimizu Junzo, Yamada Terumasa, Tanemura Masahiro, Yokoyama Shigekazu, Tsujie Masanori, Asaoka Tadafumi, Takeda Yutaka, Morimoto Osakuni, Tomokuni Akira, Doki Yuichiro, Eguchi Hidetoshi

СтатьяРандомизированное исследованиеСравнительное исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

The optimal neoadjuvant chemotherapy (NAC) regimen for patients with localized pancreatic ductal adenocarcinoma (PDAC) remains uncertain. This trial aimed to evaluate the efficacy and safety of two neoadjuvant chemotherapy (NAC) regimens, gemcitabine plus nab-paclitaxel (GA) and gemcitabine plus S-1 (GS), in patients with resectable/borderline-resectable (R/BR) PDAC.

PATIENTS AND

METHODS

Treatment-naïve patients with R/BR-PDAC were enrolled and randomly allocated. They received two cycles (2 months) of each standard protocol, followed by radical surgery for those without tumor progression in general hospitals belonging to our intergroup. The primary endpoint was to determine the superior regimen on the basis of achieving a 10% increase in the rate of patients with progression-free survival (PFS) at 2 years from allocation.

RESULTS

A total of 100 patients were enrolled, with 94 patients randomly assigned to the GS arm (N = 46) or GA arm (N = 48). The 2-year PFS rates did not show the stipulated difference [GA, 31% (24-38%)/GS, 26% (18-33%)], but the Kaplan-Myer analysis showed significance (median PFS, GA/GS 14 months/9 months, P = 0.048; HR 0.71). Secondary endpoint comparisons yielded the following results (GA/GS arm, P-value): rates of severe adverse events during NAC, 73%/78%, P = 0.55; completion rates of the stipulated NAC, 92%/83%, P = 0.71; resection rates, 85%/72%, P = 0.10; average tumor marker (CA19-9) reduction rates, -50%/-21%, P = 0.01; average numbers of lymph node metastasis, 1.7/3.2, P = 0.04; and median overall survival times, 42/22 months, P = 0.26.

CONCLUSIONS

This study found that GA and GS are viable neoadjuvant treatment regimens in R/BR-PDAC. Although the GA group exhibited a favorable PFS outcome, the primary endpoint was not achieved.

Для цитирования: Yamada Daisaku, Kobayashi Shogo, Takahashi Hidenori, Iwagami Yoshifumi, Akita Hirofumi, Asukai Kei, Shimizu Junzo, Yamada Terumasa, Tanemura Masahiro, Yokoyama Shigekazu, Tsujie Masanori, Asaoka Tadafumi, Takeda Yutaka, Morimoto Osakuni, Tomokuni Akira, Doki Yuichiro, Eguchi Hidetoshi. Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015).. Annals of surgical oncology. 2024. DOI: 10.1245/s10434-024-15199-8.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.